Menveo

Meningococcal Group Y Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm197 Protein, the active ingredient in Menveo, is a vaccine presented as a 0.5 mL vial (lyophilized powder for suspension) for intramuscular use. It induces protective immunity against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W‑135 and Y in at‑risk populations, including children, adolescents and adults.

GNH USA supplies Menveo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable cold‑chain logistics across global markets.

Menveo is a conjugate vaccine targeting the capsular polysaccharides of Neisseria meningitidis and is used for prevention of meningococcal disease. - Invasive meningococcal disease (serogroups A, C, W‑135, Y): Provides active immunity to reduce the risk of infection. - Adolescents and young adults: Lowers incidence of meningococcal disease in high‑risk age groups. - Travelers to endemic regions: Offers protection against meningococcal infection during international travel.

Common and serious adverse reactions have been reported following Menveo administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient elevation of body temperature. - Headache: mild headache occurring within 24 hours. - Fatigue: temporary feeling of tiredness. - Muscle aches: mild myalgia around the injection area.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurologic disorder reported post‑vaccination. - Seizures: infrequent occurrence, especially in febrile children. - Hypotension: sudden drop in blood pressure after injection. - Meningococcal disease despite vaccination: extremely rare breakthrough infection.

Before administering Menveo, consider the following precautions and warnings. - Pregnancy: safety not established; vaccinate only if benefit outweighs risk. - Immunocompromised patients: vaccine may elicit a reduced immune response. - Known allergy: avoid if hypersensitivity to any vaccine component, including CRM197. - Fever monitoring: observe for fever or systemic reactions after injection. - Concurrent vaccines: can be given at separate sites; follow recommended intervals. - Storage: Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Menveo may interact with other medicines or biologics; consider the following.

Major Interactions (Avoid): - Live bacterial vaccines: avoid simultaneous administration as immune response may be impaired. - Immunoglobulin therapy: may diminish vaccine efficacy if given concurrently.

Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen): may mask post‑vaccination fever, monitor temperature. - Other vaccines: schedule appropriately to avoid interference with immune response. - Immunosuppressive drugs: monitor antibody levels as response may be attenuated. - Blood products: consider timing to prevent reduced immunogenicity.